# CalciMedica

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/calcimedica

- Industry: Pharmaceuticals
- Headquarters: La Jolla, US
- Website: www.calcimedica.com/
- Total disclosed funding: $58M
- Latest round: Series D (Mar 11, 2021)
- Investors on record: 8

## About

Founded in 2006 and based in California, US, CalciMedica Inc. develops pharmaceutical drugs using small-molecule procedures that provide treatment for autoimmune disorders, organ transplant rejection, and other immune diseases. In January 2024, CalciMedica Inc. raised USD 20.4 million in PIPE funding from Deerfield Management, Soleus Capital, Stonepine Capital Management, and Aisling Capital, including Sanderling Ventures and Bering Capital. As of 2024, the company is led by its CEO, Rachel Leheny.

The company focuses on developing therapies to treat life-threatening inflammatory diseases, specifically targeting the pancreas, kidney, and lung. The firm's research is centered on CRAC (calcium release-activated calcium) channel inhibitors, which are a class of drugs designed to modulate immune responses and protect against tissue damage. CalciMedica’s lead product, Auxora™, is an intravenous formulation in development for acute pancreatitis with systemic inflammatory response syndrome (SIRS) and asparaginase-induced pancreatic toxicity (AIPT).

## Funding rounds

- Series D, Mar 11, 2021, $21M — Sanderling Ventures, Valence Life Sciences, GF Securities, Quark Venture
- Series C, May 22, 2020, $15M — Sanderling Ventures, Mesa Verde Venture Partners, Valence Life Sciences, Bering Capital
- Series A, Apr 17, 2014, $2.5M — Sanderling Ventures, SR One
- Series C, Dec 15, 2009, $12M — Sanderling Ventures, SR One, Biogen Idec New Ventures
- Series C, Jan 4, 2009, $4M — Sanderling Ventures, SR One, Biogen Idec New Ventures
- Series B, Aug 20, 2007, $2M — Sanderling Ventures, SR One
- Series A, Jul 20, 2007, $1M — SR One
- Seed, Dec 1, 2006 — SR One

## Investors

- SR One (https://capitalatlas.ai/funds/sr-one) — Seed, Series A, Series B, Series C
- Sanderling Ventures (https://capitalatlas.ai/funds/sanderling-ventures) — Series B, Series C, Series A, Series D
- Biogen Idec New Ventures (https://capitalatlas.ai/funds/biogen-idec-new-ventures) — Series C
- Mesa Verde Venture Partners (https://capitalatlas.ai/funds/mesa-verde-venture-partners) — Series C
- Valence Life Sciences (https://capitalatlas.ai/funds/valence-life-sciences) — Series C, Series D
- Bering Capital (https://capitalatlas.ai/funds/bering-capital) — Series C
- GF Securities — Series D
- Quark Venture (https://capitalatlas.ai/funds/quark-venture) — Series D